{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:50Z","timestamp":1792791950677,"version":"4.5.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Antimicrobial resistance is among the greatest threats to public health globally, and drug repurposing strategies may be advantageous to addressing this problem. Mefloquine, a drug traditionally used to treat malaria, has emerged as a promising antibiotic adjuvant, due to its ability to enhance the effectiveness of conventional antibiotics against resistant bacterial strains. In this paper, we first outline the enhancement properties of mefloquine and its mechanisms of action as an adjuvant antibiotic against multidrug-resistant bacteria. Mefloquine exhibits synergistic bacteriostatic effects when combined with colistin, \u03b2-lactams, antituberculosis drugs, quinolones, and linezolid. Potential mechanisms underlying its synergistic effects include inhibition of antibiotic efflux, disruption of bacterial cell membrane integrity, and disturbance of biofilm formation. In addition, we explore the bacteriostatic effects of several mefloquine derivatives against <jats:italic>Mycobacterium tuberculosis<\/jats:italic> and some fungi. Further, we summarize the findings of recent studies on other aspects of mefloquine activity, including its antiviral and antitumor effects. Finally, the advantages and challenges of mefloquine use as an antibiotic adjuvant in combination with antibiotics for bacterial inhibition are discussed. Overall, mefloquine shows excellent potential as an antibiotic adjuvant therapy against multidrug-resistant bacteria and is a promising candidate for combination therapy; however, further studies are needed to fully elucidate its mechanism of action and address the challenges associated with its clinical application.<\/jats:p>","DOI":"10.3389\/fcimb.2024.1470891","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:34:15Z","timestamp":1732775655000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Progress in the study of mefloquine as an antibiotic adjuvant for combination bacterial inhibition treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiaofang","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"B1","unstructured":"Therapeutic Goods Administration (TGA\n          Prescribing medicines in pregnancy database\n          \n          2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1128\/AAC.00320-12","article-title":"Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice","volume":"56","author":"Bermudez","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1086\/375352","article-title":"Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease","volume":"187","author":"Bermudez","year":"2003","journal-title":"J. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1128\/AAC.48.9.3556-3558.2004","article-title":"SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease","volume":"48","author":"Bermudez","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1128\/AAC.43.8.1870","article-title":"Mefloquine is active in vitro and in vivo against Mycobacterium avium complex","volume":"43","author":"Bermudez","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/530815","article-title":"Mefloquine and its enantiomers are active against Mycobacterium tuberculosis in vitro and in macrophages","volume":"2014","author":"Bermudez","year":"2014","journal-title":"Tuberc Res. Treat"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1128\/AAC.01614-08","article-title":"Identification and characterization of mefloquine efficacy against\u00a0JC\u00a0virus in vitro","volume":"53","author":"Brickelmaier","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1016\/j.cell.2021.10.010","article-title":"Z-form extracellular DNA is a structural component of the bacterial biofilm matrix","volume":"184","author":"Buzzo","year":"2021","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14787210.2020.1705155","article-title":"Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction","volume":"18","author":"Coates","year":"2020","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/msb.2011.71","article-title":"Systematic exploration of synergistic drug pairs","volume":"7","author":"Cokol","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo7793","article-title":"The past, present, and future of antibiotics","volume":"14","author":"Cook","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"12364","DOI":"10.1073\/pnas.0402044101","article-title":"Potent block of Cx36 and Cx50 gap junction channels by mefloquine","volume":"101","author":"Cruikshank","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104263","article-title":"Epidemiology of colistin-resistant, carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Croatia","volume":"81","author":"D\u2019Onofrio","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1128\/AAC.49.9.3707-3714.2005","article-title":"Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria","volume":"49","author":"Danelishvili","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2174\/1568026619666190304124952","article-title":"Synthesis and antibacterial activity of mefloquine-based analogs against sensitive and resistant mycobacterium tuberculosis strains","volume":"19","author":"da Silva Ara\u00fajo","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cca.2024.119701","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4155\/fmc-2018-0254","article-title":"Membrane-targeting antibiotics: recent developments outside the peptide space","volume":"11","author":"Dias","year":"2019","journal-title":"Future Med. Chem."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.104786","article-title":"Mefloquine synergism with anti-tuberculosis drugs and correlation to membrane effects: Biologic, spectroscopic and molecular dynamics simulations studies","volume":"110","author":"Dos Santos","year":"2021","journal-title":"Bioorg Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.bbamem.2015.10.018","article-title":"Molecular mechanisms of membrane targeting antibiotics","volume":"1858","author":"Epand","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1016\/S2468-2667(22)00225-0","article-title":"The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jinf.2016.11.008","article-title":"Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance","volume":"74","author":"Fern\u00e1ndez-Barat","year":"2017","journal-title":"J. Infect."},{"key":"B23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2217\/fmb-2016-0127","article-title":"Bronchial microbiome, PA biofilm-forming capacity and exacerbation in severe COPD patients colonized by P. aeruginosa","volume":"12","author":"Garcia-Nu\u00f1ez","year":"2017","journal-title":"Future Microbiol."},{"key":"B24","first-page":"95","article-title":"Pragmatic overview on acute bacterial and fungal infections of the central nervous system: a holistic update from diagnosis to treatment","volume":"46","author":"Giuliano","year":"2023","journal-title":"New Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.bmc.2011.11.006","article-title":"Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113","volume":"20","author":"Gon\u00e7alves","year":"2012","journal-title":"Bioorg Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1016\/j.ejmech.2010.09.024","article-title":"Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives","volume":"45","author":"Gon\u00e7alves","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"B27","unstructured":"Surgeon General Task Force Report on Mefloquine\n          \n          2013"},{"key":"B28","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/sj.bjp.0703638","article-title":"The antimalarial agent me\u00d8oquine inhibits ATP-sensitive K-channels","volume":"131","author":"Gribble","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(05)74932-1","article-title":"Acute fatty liver after malaria prophylaxis with mefloquine","volume":"353","author":"Grieco","year":"1999","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00314","article-title":"Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant enterobacteriaceae isolated from adult and children patients in China","volume":"10","author":"Han","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.clineuro.2011.12.010","article-title":"Efficacy of mefloquine to progressive multifocal leukoencephalopathy initially presented with parkinsonism","volume":"114","author":"Hirayama","year":"2012","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.masthead.30-1","article-title":"Carbapenem-resistant acinetobacter baumannii and enterobacteriaceae in South and Southeast Asia","volume":"30","author":"Hsu","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106309","article-title":"Mefloquine enhances the activity of colistin against antibiotic-resistant Enterobacterales in vitro and in an in vivo animal study","volume":"57","author":"Hu","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021579118","article-title":"Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection","volume":"118","author":"Jan","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mc.23407","article-title":"Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAFV600E \/NRASQ61K Malignant melanoma cells targeting intracranial tumors in a bioluminescent murine model","volume":"61","author":"Jandova","year":"2022","journal-title":"Mol. Carcinog"},{"key":"B36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd2683","article-title":"Mechanisms of drug combinations: interaction and network perspectives","volume":"8","author":"Jia","year":"2009","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202357101","article-title":"Mefloquine targets NLRP3 to reduce lipopolysaccharide-induced systemic inflammation and neural injury","volume":"24","author":"Jiang","year":"2023","journal-title":"EMBO Rep."},{"key":"B38","first-page":"290","article-title":"Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1\/minK and HERG","volume":"299","author":"Kang","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2165\/00003088-199019040-00002","article-title":"Clinical pharmacokinetics of mefloquine","volume":"19","author":"Karbwang","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1128\/JVI.80.2.1044-1046.2006","article-title":"Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo","volume":"80","author":"Kocisko","year":"2006","journal-title":"J. Virol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11121420","article-title":"Drug repurposing approaches towards defeating multidrug-resistant gram-negative pathogens: novel polymyxin\/non-antibiotic combinations","volume":"11","author":"Koh Jing Jie","year":"2022","journal-title":"Pathogens"},{"key":"B42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/clinids\/16.1.185","article-title":"Use of mefloquine for malarial chemoprophylaxis in its first year of availability in the United States","volume":"16","author":"Kozarsky","year":"1993","journal-title":"Clin. Infect. Dis."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27031003","article-title":"A review of modifications of quinoline antimalarials: mefloquine and (hydroxy)Chloroquine","volume":"27","author":"Kucharski","year":"2022","journal-title":"Molecules"},{"key":"B44","doi-asserted-by":"publisher","first-page":"210212","DOI":"10.1183\/16000617.0212-2021","article-title":"Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments","volume":"31","author":"Kumar","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1128\/AAC.44.4.848-852.2000","article-title":"Antimicrobial activities of mefloquine and a series of related compounds","volume":"44","author":"Kunin","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e00020","DOI":"10.1128\/CMR.00020-18","article-title":"Methicillin-resistant staphylococcus aureus: molecular characterization, evolution, and epidemiology","volume":"31","author":"Lakhundi","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/exd.14651","article-title":"Mefloquine causes selective mast cell apoptosis in cutaneous mastocytosis lesions by a secretory granule-mediated pathway","volume":"31","author":"Lampinen","year":"2022","journal-title":"Exp. Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.tranon.2019.06.001","article-title":"Lysosome inhibition by mefloquine preferentially enhances the cytotoxic effects of tyrosine kinase inhibitors in blast phase chronic myeloid leukemia","volume":"12","author":"Lam Yi","year":"2019","journal-title":"Transl. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","article-title":"Antibiotic resistance-the need for global solutions","volume":"13","author":"Laxminarayan","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1139\/cjpp-2016-0124","article-title":"Therapeutic effects of antibiotic drug mefloquine against cervical cancer through impairing mitochondrial function and inhibiting mTOR pathway","volume":"95","author":"Li","year":"2017","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.2147\/IDR.S427232","article-title":"Combination of AS101 and Mefloquine Inhibits Carbapenem-Resistant Pseudomonas aeruginosa in vitro and in vivo","volume":"16","author":"Li","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"B52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.micpath.2018.03.042","article-title":"Mefloquine targets \u03b2-catenin pathway and thus can play a role in the treatment of liver cancer","volume":"118","author":"Li","year":"2018","journal-title":"Microb. Pathog."},{"key":"B53","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.bbrc.2016.01.046","article-title":"Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K\/Akt\/mTOR signaling pathway","volume":"470","author":"Liu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","article-title":"Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1080\/22221751.2022.2036078","article-title":"Emergence of colistin-resistant hypervirulent Klebsiella pneumoniae (CoR-HvKp) in China","volume":"11","author":"Liu","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"B56","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1021\/jm00245a015","article-title":"Antimalarials. 7. Bis(trifluoromethyl)-.alpha.-(2-piperidyl)-4-quinolinemethanols","volume":"14","author":"Lutz","year":"1971","journal-title":"J. Med. Chem."},{"key":"B57","first-page":"29","article-title":"Inhibition of volume-regulated and calcium-activated chloride channels by the antimalarial mefloquine","volume":"295","author":"Maertens","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/jac\/dkac403","article-title":"Prevalence and characterization of piperaquine, mefloquine and artemisinin derivatives triple-resistant Plasmodium falciparum in Cambodia","volume":"78","author":"Mairet-Khedim","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bmcl.2009.11.105","article-title":"Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs","volume":"20","author":"Mao","year":"2010","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B60","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.1021\/jm900340a","article-title":"From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters","volume":"52","author":"Mao","year":"2009","journal-title":"J. Med. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.vetmic.2015.02.007","article-title":"Antiviral effect of mefloquine on feline calicivirus in vitro","volume":"176","author":"McDonagh","year":"2015","journal-title":"Vet. Microbiol."},{"key":"B62","unstructured":"GOV.UK\n          Mefloquine (Lariam) prescribing in the UK Armed Forces: 12 September 2016 to 31 March 2024\n          \n          2024"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-22-3334","article-title":"National cancer institute combination therapy platform trial with molecular analysis for therapy choice (ComboMATCH)","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e02331","DOI":"10.1128\/AAC.02331-19","article-title":"Derivatives of the antimalarial drug mefloquine are broad-spectrum antifungal molecules with activity against drug-resistant clinical isolates","volume":"64","author":"Montoya","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1002\/anie.201300258","article-title":"The absolute configuration of (+)- and (-)-erythro-mefloquine","volume":"52","author":"M\u00fcller","year":"2013","journal-title":"Angew Chem. Int. Ed Engl."},{"key":"B66","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","article-title":"Rescuing the last-line polymyxins: achievements and challenges","volume":"73","author":"Nang","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"B68","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/jinf.2002.0970","article-title":"Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine","volume":"44","author":"Nannini","year":"2002","journal-title":"J. Infect."},{"key":"B69","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ccm.2023.06.009","article-title":"Treatment of mycobacterium avium complex pulmonary disease: when should I treat and what therapy should I start","volume":"44","author":"Nguyen","year":"2023","journal-title":"Clin. Chest Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bone.2018.06.002","article-title":"Reversal of loss of bone mass in old mice treated with mefloquine","volume":"114","author":"Pacheco-Costa","year":"2018","journal-title":"Bone"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.66","article-title":"Mefloquine, an anti-malaria agent, causes reactive oxygen species-dependent cell death in mast cells via a secretory granule-mediated pathway","volume":"2","author":"Paivandy","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105127","article-title":"Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues","volume":"193","author":"Persoons","year":"2021","journal-title":"Antiviral Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1128\/AAC.04140-14","article-title":"Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor","volume":"59","author":"Piedade","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10030315","article-title":"A cell-free screen for bacterial membrane disruptors identifies mefloquine as a novel antibiotic adjuvant","volume":"10","author":"Podoll","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2016.09.002","article-title":"The rapid spread of carbapenem-resistant Enterobacteriaceae","volume":"29","author":"Potter","year":"2016","journal-title":"Drug Resist. Update"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11274-016-2190-5","article-title":"RND efflux pump mediated antibiotic resistance in Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa: a major issue worldwide","volume":"33","author":"Puzari","year":"2017","journal-title":"World J. Microbiol. Biotechnol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijantimicag.2016.04.029","article-title":"Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection","volume":"48","author":"Rodrigues-Junior","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B79","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/cid\/ciw805","article-title":"Colistin resistance in carbapenem-resistant klebsiella pneumoniae: laboratory detection and impact on mortality","volume":"64","author":"Rojas","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41579-020-00477-5","article-title":"Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis","volume":"19","author":"Rossi","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/v14020374","article-title":"Unlike chloroquine, mefloquine inhibits SARS-coV-2 infection in physiologically relevant cells","volume":"14","author":"Sacramento","year":"2022","journal-title":"Viruses"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-9-357","article-title":"The position of mefloquine as a 21st century malaria chemoprophylaxis","volume":"9","author":"Schlagenhauf","year":"2010","journal-title":"Malar J."},{"key":"B83","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.tmaid.2015.03.010","article-title":"Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe","volume":"13","author":"Schlagenhauf","year":"2015","journal-title":"Travel Med. Infect. Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1021\/ja209050k","article-title":"Determining the absolute configuration of (+)-mefloquine HCl, the side-effect-reducing enantiomer of the antimalaria drug Lariam","volume":"134","author":"Schmidt","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1089\/mdr.2022.0138","article-title":"A screening of antimalarials extends the range of known escherichia coli acrB efflux substrates and reveals two candidates with antimicrobial drug-enhancing activity","volume":"28","author":"Schuster","year":"2022","journal-title":"Microb. Drug Resist."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.2174\/1389450122666210120084406","article-title":"Antibiotic adjuvants: A promising approach to combat multidrug resistant bacteria","volume":"22","author":"Sharma","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"B87","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.canlet.2012.07.029","article-title":"Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent","volume":"326","author":"Sharma","year":"2012","journal-title":"Cancer Lett."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.jocn.2013.12.031","article-title":"Mefloquine improved progressive multifocal leukoencephalopathy in a patient with immunoglobulin A nephropathy","volume":"21","author":"Shin","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27165167","article-title":"Novel organic salts based on mefloquine: synthesis, solubility, permeability, and in vitro activity against Mycobacterium tuberculosis","volume":"27","author":"Silva","year":"2022","journal-title":"Molecules"},{"key":"B90","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/clinids\/18.2.263","article-title":"Aplastic anemia during malarial prophylaxis with mefloquine","volume":"18","author":"Stracher","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1172\/JCI64180","article-title":"Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors","volume":"123","author":"Sukhai","year":"2013","journal-title":"J. Clin. Invest."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(23)00213-X","article-title":"Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study","volume":"23","author":"Sutanto","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1158\/0008-5472.CAN-18-2192","article-title":"Disruption of endolysosomal RAB5\/7 efficiently eliminates colorectal cancer stem cells","volume":"79","author":"Takeda","year":"2019","journal-title":"Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008554","article-title":"Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-\u03b3-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors","volume":"12","author":"Tao","year":"2014","journal-title":"J. Immunother. Cancer."},{"key":"B95","year":"2017"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tmaid.2008.12.004","article-title":"Mefloquine neurotoxicity: a literature review","volume":"7","author":"Toovey","year":"2009","journal-title":"Travel Med. Infect. Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of america (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl. J. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.mimet.2009.09.021","article-title":"Use of\u00a0resazurin to detect mefloquine as an efflux-pump inhibitor in Pseudomonas aeruginosa and Escherichia coli","volume":"79","author":"Vidal-Aroca","year":"2009","journal-title":"J. Microbiol. Methods"},{"key":"B100","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cmi.2019.09.015","article-title":"Current landscape in the discovery of novel antibacterial agents","volume":"26","author":"Vila","year":"2020","journal-title":"Clin. Microbiol. Infection"},{"key":"B101","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbrc.2021.09.069","article-title":"Mefloquine as a dual inhibitor of glioblastoma angiogenesis and glioblastoma via disrupting lysosomal function","volume":"580","author":"Wan","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B102","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1021\/acs.jmedchem.5b01912","article-title":"Antibacterial diamines targeting bacterial membranes","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-443","article-title":"Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses","volume":"12","author":"Wernsdorfer","year":"2013","journal-title":"Malar J."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001913","article-title":"Multispecies biofilm architecture determines bacterial exposure to phages","volume":"20","author":"Winans","year":"2022","journal-title":"PloS Biol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"17031","DOI":"10.1038\/nmicrobiol.2017.31","article-title":"Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis","volume":"2","author":"Wong","year":"2017","journal-title":"Nat. Microbiol."},{"key":"B106","unstructured":"Launch of the WHO Report on Antimalarial Drug Efficacy, Resistance and Response: 10 Years of Surveillance, (2010\u20132019)\n          \n          2020"},{"key":"B107","unstructured":"2024"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01217","article-title":"Mefloquine inhibits esophageal squamous cell carcinoma tumor growth by inducing mitochondrial autophagy","volume":"10","author":"Xie","year":"2020","journal-title":"Front. Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/cas.13540","article-title":"Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer cells","volume":"109","author":"Xu","year":"2018","journal-title":"Cancer Sci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3892\/ol.2013.1259","article-title":"Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo","volume":"5","author":"Yan","year":"2013","journal-title":"Oncol. Lett."},{"key":"B111","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nrmicro2133","article-title":"Drug interactions and the evolution of antibiotic resistance","volume":"7","author":"Yeh","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020190","article-title":"Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda","volume":"2","author":"Yeka","year":"2005","journal-title":"PloS Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s40820-020-0409-3","article-title":"Multi-targeted antisense oligonucleotide delivery by a framework nucleic acid for inhibiting biofilm formation and virulence","volume":"12","author":"Zhang","year":"2020","journal-title":"Nanomicro Lett."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.790220","article-title":"Combined With Mefloquine, Resurrect Colistin Active in Colistin-Resistant Pseudomonas aeruginosa in vitro and in vivo","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Microbiol."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116138","article-title":"Mefloquine improves pulmonary fibrosis by inhibiting the KCNH2\/Jak2\/Stat3 signaling pathway in macrophages","volume":"171","author":"Zhou","year":"2024","journal-title":"BioMed. Pharmacother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1470891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:34:21Z","timestamp":1732775661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1470891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":115,"alternative-id":["10.3389\/fcimb.2024.1470891"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1470891","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"article-number":"1470891"}}